Toxin in Biological Technology

Bacteria pack their own demise

... have several tens of thousands of genes. toxin and antitoxin If your genetic information ... T-A genes contain instructions for both a toxin and its antitoxin. As long as the cell is ... located gets damaged or lost, the production of toxin and antitoxin comes to a halt and a time bomb ...

Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)

... Medarex to target and neutralize the effects of toxin A and toxin B, respectively, the toxins produced by the ... the requirement for anti-C. difficile toxin B antibody in addition to anti-C. ...

Novel compound may treat acute diarrhea

... signaling. "You start with one molecule of a toxin or a hormone," said Alexander Kots, Ph.D., the ... of the UT Health Science Center at Houston. "The toxin binds to a target and influences it. Soon you ... is called signal amplification. One molecule of toxin can produce millions of molecules of water." ...

Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection

... monoclonal antibody targeting the anthrax toxin protective antigen. Elusys' Anthim is designed ... continued, "Death from the effects of anthrax toxin can occur in a few days if patients are not ... 'instant protective immunity' against the anthrax toxin in a bioterrorism emergency. We believe ...

Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication

... of patients treated with Myobloc(R) (Botulinum toxin Type B) Injectable Solution has always been ... regulations. Manufacturers of botulinum toxin products have recently submitted safety ... injected into an affected muscle, botulinum toxin type B inhibits the release of the ...

New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia

... and knowledge with techniques around botulinum toxin injections lead to the best results for patients ... demonstrations with Myobloc(R) (Botulinum toxin Type B) Injectable Solution. The course can be ... review of the condition and the role of botulinum toxin type B," said Eric J. Pappert, MD, ...

New designer toxins kill Bt-resistant insect pests

... "We proposed that changing a small part of the toxin would kill the insect -- and we did it." ... gut membranes. Normal cadherin binds with the Bt toxin in a lock-and-key fashion. After the toxin binds, an enzyme hacks a bit off ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in ...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in ...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in ...

DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments

... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in ...

Researchers develop new way to see single RNA molecules inside living cells

... three times brighter." For their experiments, the team used a bacterial toxin to transport the probes into living cells a delivery technique that when ... targets, required significantly fewer probes than existing techniques. The toxin created several tiny holes in the cell membrane that allowed the probes to ...

DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments

... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in ...

DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors

... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVaxTM, has been shown to be well tolerated and immunogenic in a ...

DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer

... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in ...

PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting

... component known as the anthrax Protective Antigen (PA) of the lethal toxin complex produced by the bacterium. Preclinical studies suggest that ... of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been ...

Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies

... ago as a treatment for eyelid spasm. When it was discovered that the tiny toxin also relaxed frown lines, its cosmetic use took flight. Today, Botox has ... of Botox use (though not all physicians are experienced enough to use the toxin in all the locations listed below) Frown Lines and Worry Lines ...

Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes

... thickness and darkness) were met. In addition, like BOTOX(R) (botulinum toxin type A), which was first approved by the FDA as a medical treatment for ... . Important BOTOX (R) and BOTOX (R) Cosmetic (Botulinum toxin Type A) Information BOTOX(R) is approved for the treatment of cervical ...

Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)

... is being co-developed by the two companies for potential use as an anti- toxin therapeutic to prevent and treat inhalation anthrax. The data were ... of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been ...

STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine

... not test for STEC. The bacteria that make these toxins are called 'Shiga toxin producing' E. coli, or STEC for short." Shiga toxin is one of the most potent toxins known to man, so much so that the Centers ...

First documented case of pest resistance to biotech cotton

... Pectinophora gossypiella, which has remained susceptible to the Bt toxin in biotech cotton. Tabashnik and his colleagues' article, "Insect ... said. Although first-generation biotech cotton contained only one Bt toxin called Cry1Ac, a new variety contains both Cry1Ac and a second Bt toxin, ...

Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimer's Vaccine in 19 Countries

... the RECALL-VAX(TM) technology: The key to inactivation of amyloid-beta toxin by vaccination is to stimulate a strong antibody immune response that ... vaccinated. Moreover, by using only short fragments of the amyloid-beta toxin too small to contain T-cell epitopes, the immune response is more specific ...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

... at the cellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. Raxibacumab blocks ...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

... at the cellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. Raxibacumab blocks ...

Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields

... crop protection technology to the company's portfolio. Circle One Global markets the product Afla-Guard(R), which is aimed at reducing aflatoxin, a toxin that can develop in crops such as corn and peanuts, particularly during heat and drought stress. "The acquisition of this technology adds an ...

Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI

... evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as patients who were cured and did not have a recurrence. About Clostridium Difficile Infection CDI has ...

Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

... (CDI) Dr. Kathleen Bamford, Reader and Honorary Consultant Medical Microbiologist, Imperial College, London: Evaluation of commercial toxin detection and two nucleic acid amplification tests for the routine detection of Clostridium difficile infection Dr. Andrej Weintraub, ...

CBDM.T, The Market and Business Intelligence Company Reviews The Vaccine Market

... 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene. ...

Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation

... scientific and research offices in Gloucester, MA. About Star Scientific Star Scientific is a technology-oriented tobacco company with a toxin reduction mission. It is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins (principally ...

Cutting the cord to determine babies' health risk from toxic exposure

... emergence of improved analytical tools allowed the researchers to address newborn health risks and explore the environmental effects of a well-known toxin in a level of detail not previously available. These tools include high-speed DNA sequencing, a powerful instrumental analysis called proteomic mass ...

Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease

... plays a major role in memory formation, leads to symptoms of PD-related dementia. To test this hypothesis, her group will administer a Parkinsonian toxin to preclinical models with lowered levels of acetylcholine, then measure their performance on a battery of cognitive tests. If the preclinical models ...

US Neuropathic Pain Market Value Doubles to $5 Billion by 2018

... reuptake inhibitor tapentadol (Ortho-McNeil); a dopamine receptor agonist sodium oxybate (Jazz), and a neuromuscular blocking agent botulinum toxin A (Allergan). Early-phase products are also described in the full report. ADDITIONAL SERVICES AND REPORTS BY WWMR, INC. INCLUDE: -- US Pain ...

Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou

... also clearly expressed that they do not support its use because of its safety and questionable immunisation effects (especially as the source of the toxin used for manufacturing the attenuated living vaccine is showing signs of Atavism. The immunisation effect is also poor.) Therefore, there are serious ...

Nanosized technology has supersized effect on tumors

... FASEB Journal, the researchers describe a significant reduction of tumor growth in rabbits that were treated with nanoparticles coated with a fungal toxin called fumagillin. Human clinical trials have shown that fumagillin can be an effective cancer treatment in combination with other anticancer drugs. ...

PharmAthene Reports Year-End 2007 Financial Results

... anthracis (anthrax) spores within macrophages, potentially blocking the ability of the spores to develop into bacteria and preventing toxin production and propagation of the infection. -- Demonstrating new research showing that recombinant butyrylcholinesterase (rBChE) may ...

QuoNova Global Executive Appointments

... of contamination, corrosion and efficiency reductions. QuoNova's QSB technology disrupts microbial communication systems and by so doing inhibits toxin production, prevents biofilm formation and promotes degradation of already established biofilms. Moreover, research to date indicates that QuoNova's ...

QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp

... of contamination, corrosion and efficiency reductions. QuoNova's QSB technology disrupts microbial communication systems and by so doing inhibits toxin production, prevents biofilm formation and promotes degradation of already established biofilms. Moreover, research to date indicates that QuoNova's ...

Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.

... and marketing of specialty products. Solstice's first product, Myobloc(R) (Botulinum Toxin Type B) Injectable Solution, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold ...

NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update

... anthrax decontamination confirmation has been completed successfully and NanoLogix is currently working on additional BioTerrorism issues, such as toxin identification. The Board of Directors met on 10/22/07, with a majority of directors passing a motion to reduce director and executive stock ...

Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.

... and marketing of specialty products. Solstice's first product, MYOBLOC(R) (Botulinum Toxin Type B) Injectable Solution, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold ...